Randomization and treatment
PH1
Drug allocation was undertaken centrally according to the drug randomization number/scheme generated by the sponsor using SAS software (SAS Institute Inc., Cary, NC, USA), which assigned participants to nedosiran and placebo groups in a 2:1 ratio. Implementation of the randomization scheme was achieved using an Interactive Web Response System. Each participant received a single dose of study intervention on Day 1. A nedosiran dose of 3 mg/kg for all PH3 participants ≥ 12 years of age was used to allow comparisons between results of this study and results from a study of patients with PH1 and PH2 (PHYOX1, NCT03392896) [Participants avoided vitamin C supplements (and multivitamins) for 24 h before and during urine collections, as well as oxalate-rich foods and strenuous exercise for 24 h before each blood draw [